vs
Capri Holdings Ltd（CPRI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Capri Holdings Ltd的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 11.3%，领先1.4%），Revvity同比增速更快（5.9% vs -18.7%），Capri Holdings Ltd自由现金流更多（$183.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -15.2%）
卡普里控股是一家跨国时尚集团，注册于英属维尔京群岛，行政总部位于伦敦，运营办公室设在纽约。品牌由美国设计师迈克尔·高仕于1981年创立，主营服饰、鞋履、手表、手袋及其他配饰产品，截至2015年在全球拥有550余家门店，以及超过1500个店中店专柜。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CPRI vs RVTY — 直观对比
营收规模更大
CPRI
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出24.6%
-18.7%
净利率更高
RVTY
高出1.4%
11.3%
自由现金流更多
CPRI
多$21.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-15.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $116.0M | $98.4M |
| 毛利率 | 60.8% | — |
| 营业利润率 | 4.5% | 14.5% |
| 净利率 | 11.3% | 12.7% |
| 营收同比 | -18.7% | 5.9% |
| 净利润同比 | 121.2% | 3.9% |
| 每股收益（稀释后） | $0.96 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRIRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $856.0M | $698.9M | ||
| Q2 25 | $797.0M | $720.3M | ||
| Q1 25 | $1.6B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $878.0M | $684.0M | ||
| Q2 24 | $848.0M | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润CPRIRVTY
| Q4 25 | $116.0M | $98.4M | ||
| Q3 25 | $-28.0M | $46.7M | ||
| Q2 25 | $53.0M | $53.9M | ||
| Q1 25 | $-645.0M | $42.2M | ||
| Q4 24 | $-547.0M | $94.6M | ||
| Q3 24 | $24.0M | $94.4M | ||
| Q2 24 | $-14.0M | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率CPRIRVTY
| Q4 25 | 60.8% | — | ||
| Q3 25 | 61.0% | 53.6% | ||
| Q2 25 | 63.0% | 54.5% | ||
| Q1 25 | 64.9% | 56.5% | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 62.3% | 56.3% | ||
| Q2 24 | 63.1% | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CPRIRVTY
| Q4 25 | 4.5% | 14.5% | ||
| Q3 25 | -1.4% | 11.7% | ||
| Q2 25 | 2.0% | 12.6% | ||
| Q1 25 | -47.5% | 10.9% | ||
| Q4 24 | 2.4% | 16.3% | ||
| Q3 24 | -0.7% | 14.3% | ||
| Q2 24 | 1.3% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率CPRIRVTY
| Q4 25 | 11.3% | 12.7% | ||
| Q3 25 | -3.3% | 6.7% | ||
| Q2 25 | 6.6% | 7.5% | ||
| Q1 25 | -39.1% | 6.4% | ||
| Q4 24 | -51.2% | 13.0% | ||
| Q3 24 | 2.7% | 13.8% | ||
| Q2 24 | -1.7% | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）CPRIRVTY
| Q4 25 | $0.96 | $0.86 | ||
| Q3 25 | $-0.22 | $0.40 | ||
| Q2 25 | $0.44 | $0.46 | ||
| Q1 25 | $-5.47 | $0.35 | ||
| Q4 24 | $-4.61 | $0.77 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $-0.12 | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $154.0M | $919.9M |
| 总债务越低越好 | $234.0M | — |
| 股东权益账面价值 | $105.0M | $7.3B |
| 总资产 | $3.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.23× | — |
8季度趋势，按日历期对齐
现金及短期投资CPRIRVTY
| Q4 25 | $154.0M | $919.9M | ||
| Q3 25 | $120.0M | $931.4M | ||
| Q2 25 | $129.0M | $991.8M | ||
| Q1 25 | $107.0M | $1.1B | ||
| Q4 24 | $356.0M | $1.2B | ||
| Q3 24 | $182.0M | $1.2B | ||
| Q2 24 | $213.0M | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务CPRIRVTY
| Q4 25 | $234.0M | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | — | — |
股东权益CPRIRVTY
| Q4 25 | $105.0M | $7.3B | ||
| Q3 25 | $-74.0M | $7.4B | ||
| Q2 25 | $-17.0M | $7.6B | ||
| Q1 25 | $368.0M | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产CPRIRVTY
| Q4 25 | $3.3B | $12.2B | ||
| Q3 25 | $5.6B | $12.1B | ||
| Q2 25 | $5.5B | $12.4B | ||
| Q1 25 | $5.2B | $12.4B | ||
| Q4 24 | $5.9B | $12.4B | ||
| Q3 24 | $6.8B | $12.8B | ||
| Q2 24 | $6.6B | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比CPRIRVTY
| Q4 25 | 2.23× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 4.05× | — | ||
| Q4 24 | 1.38× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.08× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $202.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $183.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 17.9% | 21.0% |
| 资本支出强度资本支出/营收 | 1.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.74× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-134.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CPRIRVTY
| Q4 25 | $202.0M | $182.0M | ||
| Q3 25 | $-52.0M | $138.5M | ||
| Q2 25 | $-8.0M | $134.3M | ||
| Q1 25 | $-161.0M | $128.2M | ||
| Q4 24 | $309.0M | $174.2M | ||
| Q3 24 | $50.0M | $147.9M | ||
| Q2 24 | $83.0M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流CPRIRVTY
| Q4 25 | $183.0M | $161.8M | ||
| Q3 25 | $-65.0M | $120.0M | ||
| Q2 25 | $-21.0M | $115.5M | ||
| Q1 25 | $-231.0M | $112.2M | ||
| Q4 24 | $287.0M | $149.8M | ||
| Q3 24 | $30.0M | $125.6M | ||
| Q2 24 | $67.0M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率CPRIRVTY
| Q4 25 | 17.9% | 21.0% | ||
| Q3 25 | -7.6% | 17.2% | ||
| Q2 25 | -2.6% | 16.0% | ||
| Q1 25 | -14.0% | 16.9% | ||
| Q4 24 | 26.9% | 20.5% | ||
| Q3 24 | 3.4% | 18.4% | ||
| Q2 24 | 7.9% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度CPRIRVTY
| Q4 25 | 1.9% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 4.2% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 2.3% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率CPRIRVTY
| Q4 25 | 1.74× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -0.15× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.08× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRI
| Michael Kors Segment | $593.0M | 58% |
| Other | $379.0M | 37% |
| Jimmy Choo Segment | $53.0M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
